#1 Clinical Trials Search in Europe

Felzartamab

Felzartamab, also known as MOR202 or HIB202, is a novel drug being studied in clinical trials for various kidney-related autoimmune conditions. These trials aim to evaluate the safety, efficacy, and potential benefits of Felzartamab in treating conditions such as Lupus Nephritis, Antibody-mediated Rejection in kidney transplant recipients, and IgA Nephropathy. The drug is designed to target CD38, a protein found on certain immune cells, and may offer new hope for patients with these challenging conditions.

Table of Contents

What is Felzartamab?

Felzartamab is a new medication being studied for various kidney-related conditions. It is a type of drug called a monoclonal antibody, which is a laboratory-made protein designed to target specific cells in the body. Felzartamab is also known by several other names, including MOR202, HIB202, TJ202, MOR03087, and BIIB148[2][3]. These different names are often used in research settings or by different pharmaceutical companies involved in its development.

What Conditions Does Felzartamab Treat?

Felzartamab is being studied for several kidney-related conditions:

  • Lupus Nephritis (LN): This is a type of kidney inflammation caused by systemic lupus erythematosus, an autoimmune disease[1].
  • Antibody-mediated Rejection (AMR): This is a complication that can occur after kidney transplantation, where the body’s immune system attacks the transplanted kidney[2][3].
  • IgA Nephropathy: This is a kidney disease caused by buildup of immunoglobulin A (IgA) in the kidneys, leading to inflammation[4].

How Does Felzartamab Work?

Felzartamab is designed to target a specific protein called CD38, which is found on the surface of certain immune cells. By binding to CD38, Felzartamab can affect the behavior of these immune cells[3]. In conditions like lupus nephritis, antibody-mediated rejection, and IgA nephropathy, the immune system is often overactive or misdirected. By targeting CD38, Felzartamab may help to reduce this harmful immune activity and protect the kidneys from damage.

Current Clinical Trials

Felzartamab is currently being studied in several clinical trials:

  • A study for patients with Lupus Nephritis is evaluating the safety and effectiveness of Felzartamab when added to standard treatments[1].
  • Two studies are looking at Felzartamab for Antibody-mediated Rejection in kidney transplant recipients. These trials are comparing Felzartamab to a placebo (a substance with no active medication) to see if it can help prevent or treat rejection of transplanted kidneys[2][3].
  • A study for patients with IgA Nephropathy is testing different doses of Felzartamab to see if it can reduce protein in the urine, which is a sign of kidney damage[4].

How is Felzartamab Administered?

In the clinical trials, Felzartamab is given as an intravenous infusion, which means it’s delivered directly into a vein. The frequency of administration varies depending on the specific trial and condition being treated. For example:

  • In some studies, it’s given weekly for the first month, then every four weeks after that[3].
  • Other trials may use different schedules, such as specified doses on specified days[1].

The exact dosing schedule would be determined by a doctor if Felzartamab becomes approved for general use.

Safety and Side Effects

As with any new medication, understanding the safety profile and potential side effects of Felzartamab is a crucial part of the ongoing clinical trials. Researchers are carefully monitoring:

  • The number and types of adverse events (side effects) that occur during treatment[1][2].
  • Any changes in laboratory test results, vital signs, or heart activity (ECG) that might indicate safety concerns[2].
  • The development of anti-drug antibodies, which are proteins the body might produce in response to the medication[2][3].

It’s important to note that the full safety profile of Felzartamab is still being determined through these clinical trials.

Future Prospects

The ongoing clinical trials will help determine how effective and safe Felzartamab is for treating various kidney conditions. Researchers are looking at several important outcomes, including:

  • Changes in kidney function, measured by tests like estimated glomerular filtration rate (eGFR)[2][3].
  • Reduction in protein in the urine, which is a sign of kidney health[1][4].
  • Improvements in kidney biopsy results[2][3].
  • How long the transplanted kidneys survive in patients with antibody-mediated rejection[2].

If these trials show positive results, Felzartamab could become an important new treatment option for patients with these challenging kidney conditions. However, it’s important to remember that the drug is still in the testing phase, and more research is needed before it can be approved for general use.

Aspect Details
Drug Name Felzartamab (also known as MOR202, HIB202, BIIB148)
Drug Type Fully human CD38 monoclonal antibody
Administration Intravenous infusion
Conditions Studied Lupus Nephritis, Antibody-mediated Rejection in kidney transplants, IgA Nephropathy
Primary Outcomes Safety, tolerability, adverse events, efficacy in reducing proteinuria
Secondary Outcomes Changes in kidney function, biomarkers, immunological parameters, quality of life measures
Trial Phases Phase 1b, Phase 2, Phase 3
Trial Designs Randomized, placebo-controlled, double-blind, multi-center
Duration Varies by trial, ranging from 12 months to 2 years

FAQ

  • What is Felzartamab? Felzartamab is a fully human CD38 monoclonal antibody being studied as a potential treatment for various kidney-related autoimmune conditions. It's also known by other names such as MOR202, HIB202, and BIIB148.
  • What conditions is Felzartamab being tested for? Felzartamab is being tested in clinical trials for Lupus Nephritis, Antibody-mediated Rejection in kidney transplant recipients, and IgA Nephropathy.
  • How is Felzartamab administered? Felzartamab is administered through intravenous infusion. The dosing schedule varies depending on the specific trial and condition being treated.
  • What are the main goals of the Felzartamab clinical trials? The main goals of these trials are to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of Felzartamab in treating the targeted conditions. Researchers are also looking at its effects on various biomarkers and clinical outcomes specific to each condition.
  • Are there any known side effects of Felzartamab? The clinical trials are designed to monitor and assess potential side effects. Adverse events, laboratory abnormalities, and other safety measures are being closely tracked. However, specific side effects are not detailed in the provided information and would be determined as the trials progress.

Ongoing Clinical Trials on Felzartamab

  • A Study of Felzartamab for Kidney Transplant Patients with Late Isolated Microvascular Inflammation

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia France Germany Spain

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study of Felzartamab for Patients with Late Antibody-Mediated Rejection After Kidney Transplant

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia France Germany Spain

  • Study of Felzartamab for Patients with Membranous Nephropathy Resistant to Anti-CD20 Therapy

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

Glossary

  • Felzartamab: A fully human CD38 monoclonal antibody being studied as a potential treatment for various kidney-related autoimmune conditions.
  • Lupus Nephritis (LN): A kidney inflammation caused by systemic lupus erythematosus (SLE), an autoimmune disease.
  • Antibody-mediated Rejection (AMR): A type of transplant rejection where the recipient's immune system produces antibodies against the transplanted organ.
  • IgA Nephropathy: A kidney disease caused by deposits of the protein immunoglobulin A (IgA) in the kidneys.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Used in the treatment of various diseases.
  • CD38: A protein found on the surface of many immune cells and some cancer cells, which is the target of Felzartamab.
  • Intravenous Infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Biomarker: A measurable indicator of a biological state or condition, often used to track the progress of a disease or the effects of treatment.
  • Glomerular Filtration Rate (GFR): A measure of how well the kidneys are filtering waste from the blood.
  • Proteinuria: The presence of excess proteins in the urine, which can be a sign of kidney disease.
  • Donor-specific Antibodies (DSA): Antibodies produced by a transplant recipient that are specific to the donor's human leukocyte antigens (HLAs).
  • Biopsy: A medical procedure where a small sample of tissue is taken from the body for examination.

References

  1. https://clinicaltrials.gov/study/NCT06064929
  2. https://clinicaltrials.eu/trial/study-of-felzartamab-for-patients-with-late-antibody-mediated-rejection-after-kidney-transplant/
  3. https://clinicaltrials.gov/study/NCT05021484
  4. https://clinicaltrials.gov/study/NCT05065970